COMPANY PROFILE // THE 014 REPORT
Tenaya Therapeutics, Inc.
TNYA (Nasdaq)
Assembled from 3 government sources in 0.1 s
FLAGS · DISCLOSURE · SUMMARY
Missing or hidden
- Amber4 8-K Item 5.02 filings (officer or director departures or appointments) in the last 12 months, most recently 2026-06-29: a pattern of leadership change.
- Amber8-K Item 3.01 filed: notice of delisting, of a failed continued-listing rule, or of a transfer of listing on 2026-01-30 and 1 more time (last 24 months).
✓ SEC filings✓ State registrationpossible match✗ LEI✗ SAM registration✗ IRS return✗ Website✗ Lobbying registration
No LEI, no SAM registration, no IRS return, no website, no lobbying registration on record.
Tenaya Therapeutics, Inc. is an SEC-registered operating company in biological products, (no diagnostic substances), incorporated in DE, based in South San Francisco, CA; listed as TNYA (Nasdaq).[source] It has filed 70 documents with the SEC in the last 12 months; the latest is Form 4, filed 2026-11-18.[source] Its largest institutional holders on 13F filings are VANGUARD CAPITAL MANAGEMENT LLC, MILLENNIUM MANAGEMENT LLC, CITADEL ADVISORS LLC (as of 2026-06-30).[source] Seraphix flags 2 items from these records: 8-K Item 3.01 filed; 4 8-K Item 5.02 filings (officer or director departures or appointments) in the last 12 months, most recently 2026-06-29.[source]
- red0
- amber2
- info0
- VANGUARD CAPITAL MANAGEMENT LLC$5.2M
- MILLENNIUM MANAGEMENT LLC$4.8M
- CITADEL ADVISORS LLC$3.4M
- RENAISSANCE TECHNOLOGIES LLC$3.2M
- BlackRock, Inc.$3.0M
- Empery Asset Management, LP$2.9M
- MARSHALL WACE, LLP$2.6M
- Burkehill Global Management, LP$1.5M
RECORD · WEB
Ask about this entity
Answers come from this 014 first; every line is marked RECORD (our record, linked) or WEB (a web page, credited and linked).
PEOPLE · COUNSEL · LINKS
Leadership, advisers and links
Officers and directors (Forms 3, 4, 5)
- Ali Faraz · Chief Executive Officer (Director,Officer) · latest Form 4 2026-02-17 · filing · LinkedIn search
- Higa Tomohiro · SVP, Finance (Officer) · latest Form 4 2026-02-17 · filing · LinkedIn search
- Tingley Whittemore · Chief Medical Officer (Officer) · latest Form 4 2026-02-17 · filing · LinkedIn search
- Burroughs Amy L. · Director · latest Form 4 2025-05-30 · filing · LinkedIn search
- GOEDDEL DAVID V · Director,10% owner · latest Form 4 2025-05-30 · filing · LinkedIn search
- Lee June · Director · latest Form 4 2025-05-30 · filing · LinkedIn search
- Parschauer Karah Herdman · Director · latest Form 4 2025-05-30 · filing · LinkedIn search
- Srivastava Deepak · Director · latest Form 4 2025-05-30 · filing · LinkedIn search
- Stehman-Breen Catherine · Director · latest Form 4 2025-05-30 · filing · LinkedIn search
- Walsh Jeffrey T. · Director · latest Form 4 2025-05-30 · filing · LinkedIn search
- Williams R Sanders · Director · latest Form 4 2025-05-30 · filing · LinkedIn search
As reported to the SEC by the insiders themselves; SEC insider transactions data sets (Forms 3, 4, 5): 2026q1, 2025q4, 2025q3, 2025q2.
EVERY LIST AND SOURCE · DATED
Checked and clear
26 lists and sources checked: 25 CLEAR, 1 POSSIBLE MATCH, 0 MATCH. Screening lists are checked when this 014 is built; the enforcement and registry sources at the last company-engine build. Each date is the date of that check.
EVERY IDENTIFIER · LINKED
ID crosswalk
| Identifier | Value | Record |
|---|---|---|
| SEC CIK | 0001858848 | source |
| EIN | 81-3789973 | source |
| California SOS entity | 1149240-06-171-1061031 | record |
| California SOS entity | 1127115-11-161-1061031 | record |
| California SOS entity | 1127116-11-161-1061031 | record |
| Business address (SEC) | 171 OYSTER POINT BLVD., SUITE 500, SOUTH SAN FRANCISCO, CA, 94080 | source |
Does not exist in the records we hold: LEI, UEI, NY DOS ID, FDIC certificate.
EACH FEEDS WATCH
Dates coming up
- 2027-03-31 · in 131 days · Next 10-K due (period ended 2026-12-31; Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company) (computed from the fiscal year end and filer status)
- 2027-05-15 · in 176 days · Next 10-Q due (period ended 2027-03-31; Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company) (computed from the fiscal year end and filer status)
PEERS BY SIC CODE
Industry context
SIC 2836 (biological products, (no diagnostic substances)): 183 companies in our records share this code.
federal dollars
lobbying filings
SEC filings in 12 months
flags
Peers, each with its 014
- AMGEN INC · 123 SEC filings in 12 months · 1 flag · $507.4M federal (possible match)
- Vir Biotechnology, Inc. · 117 SEC filings in 12 months · 1 flag · $65.9M federal (possible match)
- Vericel Corp · 109 SEC filings in 12 months · 1 flag · $37.3M federal (possible match)
- Coherus Oncology, Inc. · 53 SEC filings in 12 months · 3 flags · $11.8M federal (possible match)
- BIO-TECHNE Corp · 77 SEC filings in 12 months · 1 flag · $6.6M federal (possible match)
- Twist Bioscience Corp · 337 SEC filings in 12 months · 2 flags · $5.9M federal (possible match)
- Adaptive Biotechnologies Corp · 185 SEC filings in 12 months · 1 flag · $1.9M federal (possible match)
- AGENUS INC · 82 SEC filings in 12 months · 3 flags · $613K federal (possible match)
- REPLIGEN CORP · 89 SEC filings in 12 months · 1 flag · $457K federal (possible match)
- Revolution Medicines, Inc. · 171 SEC filings in 12 months · 2 flags · $15K federal (possible match)
- RECURSION PHARMACEUTICALS, INC. · 174 SEC filings in 12 months · 1 flag
- GILEAD SCIENCES, INC. · 173 SEC filings in 12 months
ADDRESS · ZIP CODE
Location context
At the same address (3)
- Surrozen, Inc./DE · SEC registrant
- Maze Therapeutics, Inc. · SEC registrant
SHARED PEOPLE · SHARED ADDRESS
Network neighbours
Shared directors and officers
- Eledon Pharmaceuticals, Inc. · Lee June
- Ultragenyx Pharmaceutical Inc. · Parschauer Karah Herdman
- Evolus, Inc. · Parschauer Karah Herdman
- Dyne Therapeutics, Inc. · Stehman-Breen Catherine
SEC registrants at the same address
EVERY SOURCE · NEWEST FIRST
One timeline
- 2026-11-16 filing SCHEDULE 13D/A · SEC EDGAR
- 2026-11-04 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-11-04 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-10-23 filing DEFA14A · SEC EDGAR
- 2026-10-23 filing Proxy statement · SEC EDGAR
- 2026-10-13 filing PRE 14A · SEC EDGAR
- 2026-08-17 filing 144 · SEC EDGAR
- 2026-08-17 filing 144 · SEC EDGAR
- 2026-08-05 filing S-8 · SEC EDGAR
- 2026-08-05 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-08-05 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-07-02 filing 8-K items 1.02 · SEC EDGAR
- 2026-06-29 officer change 8-K items 5.02,7.01,9.01 · SEC EDGAR
- 2026-05-29 officer change 8-K items 5.02,5.07,9.01 · SEC EDGAR
- 2026-05-06 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-05-06 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-04-16 filing ARS · SEC EDGAR
- 2026-04-16 filing DEFA14A · SEC EDGAR
- 2026-04-16 filing Proxy statement · SEC EDGAR
- 2026-03-11 filing Annual report (10-K) · SEC EDGAR
- 2026-03-11 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-03-05 filing 8-K items 1.01 · SEC EDGAR
- 2026-02-26 filing SCHEDULE 13D/A · SEC EDGAR
- 2026-02-25 filing 144 · SEC EDGAR
- 2026-02-25 filing 144 · SEC EDGAR
- 2026-02-20 filing 144 · SEC EDGAR
- 2026-02-20 filing 144 · SEC EDGAR
- 2026-02-17 filing 144 · SEC EDGAR
- 2026-02-17 filing 144 · SEC EDGAR
- 2026-02-12 filing SCHEDULE 13D/A · SEC EDGAR
161 earlier entries
- 2026-02-11 filing 144
- 2026-02-11 filing 144
- 2026-02-10 filing 144
- 2026-02-10 filing 144
- 2026-02-03 filing S-8
- 2026-01-30 officer change 8-K items 3.01,5.02,9.01
- 2026-01-02 officer change 8-K items 5.02
- 2025-12-17 filing SCHEDULE 13D/A
- 2025-12-12 filing 8-K items 1.01,7.01,9.01
- 2025-12-12 filing 424B5
- 2025-12-11 filing 424B5
- 2025-12-11 filing 8-K items 7.01,8.01,9.01
- 2025-11-10 filing Quarterly report (10-Q)
- 2025-11-10 filing 8-K items 2.02,9.01
- 2025-11-07 filing 8-K items 8.01
- 2025-09-10 filing UPLOAD
- 2025-09-04 filing CORRESP
- 2025-08-26 filing UPLOAD
- 2025-08-18 filing 144
- 2025-08-18 filing 144
- 2025-08-06 filing Quarterly report (10-Q)
- 2025-08-06 filing 8-K items 2.02,9.01
- 2025-05-30 filing 8-K items 5.07
- 2025-05-30 insider First Form 3/4/5 on record for Burroughs Amy L. (Director)
- 2025-05-30 insider First Form 3/4/5 on record for GOEDDEL DAVID V (Director,10% owner)
- 2025-05-30 insider First Form 3/4/5 on record for Lee June (Director)
- 2025-05-30 insider First Form 3/4/5 on record for Parschauer Karah Herdman (Director)
- 2025-05-30 insider First Form 3/4/5 on record for Srivastava Deepak (Director)
- 2025-05-30 insider First Form 3/4/5 on record for Stehman-Breen Catherine (Director)
- 2025-05-30 insider First Form 3/4/5 on record for Walsh Jeffrey T. (Director)
- 2025-05-30 insider First Form 3/4/5 on record for Williams R Sanders (Director)
- 2025-05-16 insider First Form 3/4/5 on record for Ali Faraz (Chief Executive Officer)
- 2025-05-16 insider First Form 3/4/5 on record for Higa Tomohiro (SVP, Finance)
- 2025-05-16 insider First Form 3/4/5 on record for Tingley Whittemore (Chief Medical Officer)
- 2025-05-14 filing SCHEDULE 13D/A
- 2025-05-07 filing Quarterly report (10-Q)
- 2025-05-07 filing 8-K items 2.02,9.01
- 2025-04-18 filing 8-K items 3.01
- 2025-04-17 filing ARS
- 2025-04-17 filing DEFA14A
- 2025-04-17 filing Proxy statement
- 2025-03-31 filing EFFECT
- 2025-03-28 filing 8-K items 2.05
- 2025-03-27 filing CORRESP
- 2025-03-26 filing UPLOAD
- 2025-03-21 filing S-3
- 2025-03-10 filing 144
- 2025-03-10 filing 144
- 2025-03-10 filing Annual report (10-K)
- 2025-03-10 filing 8-K items 2.02,9.01
- 2025-03-07 filing SCHEDULE 13D/A
- 2025-03-07 filing SCHEDULE 13D/A
- 2025-03-04 filing 8-K items 1.01,7.01,8.01,9.01
- 2025-03-04 filing 424B5
- 2025-03-03 filing 424B5
- 2025-03-03 filing 424B3
- 2025-02-07 filing S-8
- 2025-02-07 officer change 8-K items 5.02
- 2025-01-28 officer change 8-K items 5.02
- 2024-12-17 filing 8-K items 7.01,8.01,9.01
- 2024-12-17 officer change 8-K items 5.02
- 2024-11-06 filing Quarterly report (10-Q)
- 2024-11-06 filing 8-K items 2.02,9.01
- 2024-09-17 filing S-8
- 2024-09-16 officer change 8-K items 5.02,9.01
- 2024-08-16 filing 144
- 2024-08-16 filing 144
- 2024-08-08 filing Quarterly report (10-Q)
- 2024-08-08 officer change 8-K items 2.02,5.02,9.01
- 2024-07-25 officer change 8-K items 5.02
- 2024-06-27 officer change 8-K items 5.02
- 2024-05-31 filing 8-K items 5.07
- 2024-05-14 filing Quarterly report (10-Q)
- 2024-05-14 filing 8-K items 2.02,2.05,9.01
- 2024-04-17 filing ARS
- 2024-04-17 filing DEFA14A
- 2024-04-17 filing Proxy statement
- 2024-03-18 filing Annual report (10-K)
- 2024-03-18 filing 8-K items 2.02,9.01
- 2024-03-05 filing 144
- 2024-02-20 filing 144
- 2024-02-16 filing 144
- 2024-02-16 filing 144
- 2024-02-16 filing 144
- 2024-02-14 filing SC 13D/A
- 2024-02-08 filing 424B5
- 2024-02-08 filing 8-K items 1.01,7.01,9.01
- 2024-01-31 filing S-8
- 2023-11-08 filing Quarterly report (10-Q)
- 2023-11-08 filing 8-K items 2.02,9.01
- 2023-08-29 filing 144
- 2023-08-16 filing 144
- 2023-08-16 filing 144
- 2023-08-09 filing Quarterly report (10-Q)
- 2023-08-09 filing 8-K items 2.02,9.01
- 2023-06-12 officer change 8-K items 5.02,5.03,5.07,9.01
- 2023-05-10 filing Quarterly report (10-Q)
- 2023-05-10 filing 8-K items 2.02,9.01
- 2023-04-27 filing ARS
- 2023-04-27 filing DEFA14A
- 2023-04-27 filing Proxy statement
- 2023-04-17 filing PRE 14A
- 2023-03-21 filing 8-K items 5.03,9.01
- 2023-03-13 filing 8-K items 7.01
- 2023-03-08 filing S-8
- 2023-03-08 filing Annual report (10-K)
- 2023-03-08 filing 8-K items 2.02,9.01
- 2023-02-21 filing SC 13D/A
- 2022-12-07 officer change 8-K items 5.02,9.01
- 2022-12-07 filing SC 13D/A
- 2022-12-01 filing SC 13D
- 2022-11-28 filing SC 13D/A
- 2022-11-17 filing 8-K items 1.01,8.01,9.01
- 2022-11-17 filing 424B5
- 2022-11-16 filing 424B5
- 2022-11-10 filing Quarterly report (10-Q)
- 2022-11-10 filing 8-K items 2.02,9.01
- 2022-08-17 filing EFFECT
- 2022-08-17 filing 424B5
- 2022-08-15 filing CORRESP
- 2022-08-12 filing UPLOAD
- 2022-08-10 filing 8-K items 1.01,9.01
- 2022-08-10 filing S-3
- 2022-08-10 filing Quarterly report (10-Q)
- 2022-08-10 filing 8-K items 2.02,9.01
- 2022-06-10 filing 8-K items 5.07
- 2022-05-11 filing Quarterly report (10-Q)
- 2022-05-11 filing 8-K items 2.02,9.01
- 2022-04-28 filing DEFA14A
- 2022-04-28 filing Proxy statement
- 2022-03-23 filing S-8
- 2022-03-23 filing Annual report (10-K)
- 2022-03-23 filing 8-K items 2.02,9.01
- 2021-12-22 officer change 8-K items 5.02,9.01
- 2021-11-22 officer change 8-K items 5.02,9.01
- 2021-11-10 filing Quarterly report (10-Q)
- 2021-11-10 filing 8-K items 2.02,9.01
- 2021-09-08 filing Quarterly report (10-Q)
- 2021-09-08 filing 8-K items 2.02,9.01
- 2021-08-09 filing SC 13D
- 2021-08-03 filing 8-K items 5.03,7.01,9.01
- 2021-08-02 filing SEC STAFF LETTER
- 2021-07-30 filing S-8
- 2021-07-30 filing 424B4
- 2021-07-29 filing EFFECT
- 2021-07-29 filing S-1MEF
- 2021-07-27 filing CERT
- 2021-07-27 filing CORRESP
- 2021-07-27 filing CORRESP
- 2021-07-26 filing CORRESP
- 2021-07-26 filing S-1/A
- 2021-07-23 filing 8-A12B
- 2021-07-15 filing UPLOAD
- 2021-07-09 filing CORRESP
- 2021-07-09 filing Registration (S-1)
- 2021-06-24 filing UPLOAD
- 2021-06-16 filing DRS/A
- 2021-06-15 filing DRSLTR
- 2021-06-10 filing SEC STAFF LETTER
- 2021-06-03 filing UPLOAD
- 2021-05-07 filing DRS
RENDERED FROM THIS PAGE
Relationship graph
Holders from 13F filings, subsidiaries from the GLEIF tree (by LEI), lobbying firms from LDA (possible match), agencies from USAspending, people from Forms 3/4/5, counsel from Exhibit 5.1, shared boards from Forms 3/4/5.
DATA MOTION // NEWEST FIRSTWhat changed
- 2026-11-04 (within 30 days) 10-Q filed
- 2026-11-04 (within 30 days) 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-10-23 (within 30 days) DEFA14A filed
- 2026-10-23 (within 30 days) DEF 14A filed
- 2026-10-13 (older) PRE 14A filed
- 2026-10-09 (older) Form 5500 received for plan year ending 2025-12-31 (plan no. 001)
- 2026-08-05 (older) S-8 filed
- 2026-08-05 (older) 10-Q filed
Dot rule: red = within 7 days, amber = within 30 days, green = older. Measured against 2026-11-20; the colour is also written out in words.
COUNTS FROM THIS PAGERelationships at a glance
PRICE · FILINGS · POSTS · NEWSMarket & news
- Price
- NASDAQ:TNYA The chart widget (TradingView) shows the price and the previous session's close. Seraphix publishes no price of its own.
- Open in
Open in…
Price and chart
News
Analyst estimates and earnings
Institutional holders
Short interest
Official social
Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.
- Financials
- Filed figures: published SEC values, each linked to its filing.
- Official posts
- Links to posts from the company's and agencies' verified accounts: not connected yet.
- News
- Article links (headline, date, link): not connected yet.
EVERY RESOLVED IDENTIFIER1. Identity
8 possible matches held apart, matched by name only, not counted above.
| Identifier | Value | How it was resolved | Source |
|---|---|---|---|
| SEC CIK | 1858848 | id:sec-anchor: the SEC registrant record of this company | SEC EDGAR |
| Ticker / exchange | TNYA / Nasdaq | SEC company record: ticker and exchange as listed on the SEC company record | SEC EDGAR |
| EIN | 813789973 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001858848 | SEC EDGAR / IRS |
| CUSIP | 87990A106 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001858848 | SEC EDGAR |
possible match: matched by name only, not merged (3)
Identifiers carried by records that share the company's exact name. Not merged into the identity above.
| Identifier | Value | How it was resolved | Source |
|---|---|---|---|
| EPA FRS id | 110071261049 (TENAYA THERAPEUTICS) | name-exact: exact name match to 'Tenaya Therapeutics, Inc.' (no other entity shares the name) | EPA ECHO facilities |
| EPA FRS id | 110071380261 (TENAYA THERAPEUTICS) | name-exact: exact name match to 'Tenaya Therapeutics, Inc.' (no other entity shares the name) | EPA ECHO facilities |
| EPA FRS id | 110070425784 (TENAYA THERAPEUTICS INC) | name-exact:legal-name: same registered legal name as 'Tenaya Therapeutics, Inc.' | EPA ECHO facilities |
AS FILED · EACH WITH ITS DATE AND FILING2. Filed figures
Key figures (annual filing)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Net income (loss) (fiscal year ended 2025-12-31) | -$90,597,000 | 2025-12-31 | 10-K, XBRL NetIncomeLoss | as filed | 2026-11-20 15:04 UTC | Report an error |
| Total assets (at 2025-12-31) | $146,921,000 | 2025-12-31 | 10-K, XBRL Assets | as filed | 2026-11-20 15:04 UTC | Report an error |
| Stockholders' equity (at 2025-12-31) | $123,265,000 | 2025-12-31 | 10-K, XBRL StockholdersEquity | as filed | 2026-11-20 15:04 UTC | Report an error |
| Cash and cash equivalents (at 2025-12-31) | $100,547,000 | 2025-12-31 | 10-K, XBRL CashAndCashEquivalentsAtCarryingValue | as filed | 2026-11-20 15:04 UTC | Report an error |
Company profile facts (SEC)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| SEC entity type | operating | 2026-11-18 | SEC EDGAR company profile | as filed | 2026-11-20 15:04 UTC | Report an error |
| SIC industry | 2836 Biological Products, (No Diagnostic Substances) | 2026-11-18 | SEC EDGAR company profile | as filed | 2026-11-20 15:04 UTC | Report an error |
| State of incorporation | DE | 2026-11-18 | SEC EDGAR company profile | as filed | 2026-11-20 15:04 UTC | Report an error |
| Fiscal year end (MMDD) | 1231 | 2026-11-18 | SEC EDGAR company profile | as filed | 2026-11-20 15:04 UTC | Report an error |
| Business address | 171 OYSTER POINT BLVD., SUITE 500, SOUTH SAN FRANCISCO, CA, 94080 | 2026-11-18 | SEC EDGAR company profile | as filed | 2026-11-20 15:04 UTC | Report an error |
| Exchanges | Nasdaq | 2026-11-18 | SEC EDGAR company profile | as filed | 2026-11-20 15:04 UTC | Report an error |
Other filed values
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Operating cash flow (fiscal year ended 2025-12-31) | -$68,264,000 | 2025-12-31 | 10-K, XBRL NetCashProvidedByUsedInOperatingActivities | as filed | 2026-11-20 15:04 UTC | Report an error |
| Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31) | $618,000 | 2025-12-31 | 10-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment | as filed | 2026-11-20 15:04 UTC | Report an error |
| Operating lease liabilities (at 2025-12-31) | $10,830,000 | 2025-12-31 | 10-K, XBRL OperatingLeaseLiability | as filed | 2026-11-20 15:04 UTC | Report an error |
| Plan (pension, plan no. 001) | TENAYA THERAPEUTICS, INC. 401(K) PLAN: 135 participants, assets $12,099,340 | 2025-12-31 | DOL EBSA Form 5500 public datasets (dataset) | as filed | 2026-11-20 15:04 UTC | Report an error |
Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-04 · accession 0001193125-26-447354
| Item | Value | Period | Form | Filed | Accession | Retrieved | Report |
|---|---|---|---|---|---|---|---|
| Revenue | $1,697,000 | 3 months ended 2026-09-30 | 10-Q | 2026-11-04 | 0001193125-26-447354 | 2026-11-20 15:04 UTC | Report an error |
| Net income (loss) | -$18,938,000 | 3 months ended 2026-09-30 | 10-Q | 2026-11-04 | 0001193125-26-447354 | 2026-11-20 15:04 UTC | Report an error |
| Cash and cash equivalents | $66,797,000 | at 2026-09-30 | 10-Q | 2026-11-04 | 0001193125-26-447354 | 2026-11-20 15:04 UTC | Report an error |
| Contract liabilities, current | $5,663,000 | at 2026-09-30 | 10-Q | 2026-11-04 | 0001193125-26-447354 | 2026-11-20 15:04 UTC | Report an error |
| Contract liabilities, noncurrent | $2,876,000 | at 2026-09-30 | 10-Q | 2026-11-04 | 0001193125-26-447354 | 2026-11-20 15:04 UTC | Report an error |
Values as filed in XBRL (SEC company facts); quarterly values are the filer's own 3-month figures, never derived.
No estimates: every value is as filed and links to the filing it came from.
Registration: the SEC filer status is under "Company profile facts (SEC)" above. SAM.gov registration status: not held yet.
NEWEST FIRST · EACH LINKS TO ITS FILING3. Registration and filing timeline
- 2026-11-04 Filing 10-Q filed
- 2026-11-04 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-10-23 Filing DEFA14A filed
- 2026-10-23 Filing DEF 14A filed
- 2026-10-13 Filing PRE 14A filed
- 2026-10-09 Filing Form 5500 received for plan year ending 2025-12-31 (plan no. 001)
- 2026-08-05 Filing S-8 filed
- 2026-08-05 Filing 10-Q filed
- 2026-08-05 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-07-02 Filing 8-K filed: Item 1.02 agreement terminated
- 2026-06-29 Filing 8-K filed: Item 5.02 officer or director change; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-05-29 Filing 8-K filed: Item 5.02 officer or director change; Item 5.07 shareholder vote; Item 9.01 exhibits
- 2026-05-06 Filing 10-Q filed
- 2026-05-06 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-04-16 Filing ARS filed
- 2026-04-16 Filing DEFA14A filed
- 2026-04-16 Filing DEF 14A filed
- 2026-03-11 Filing 10-K filed
- 2026-03-11 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-03-05 Filing 8-K filed: Item 1.01 material agreement
- 2026-02-03 Filing S-8 filed
- 2026-01-30 Filing 8-K filed: Item 3.01 delisting notice; Item 5.02 officer or director change; Item 9.01 exhibits
- 2026-01-02 Filing 8-K filed: Item 5.02 officer or director change
- 2025-12-12 Filing 8-K filed: Item 1.01 material agreement; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2025-12-12 Filing 424B5 filed
2 earlier entries
- 2025-12-11 Filing 424B5 filed
- 2022-10-04 Record plan effective date: TENAYA THERAPEUTICS, INC. 401(K) PLAN
8-K item text, as filed (excerpts)
- 2026-11-04 8-K Item 2.02, Results of Operations and Financial Condition
On November 4, 2026, Tenaya Therapeutics, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2026 (“Earnings Press Release”). The full text of the Earnings Press Release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The information furnished in this Item 2.02 and Item 9.01 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a… the 8-K · retrieved 2026-11-20 15:04 UTC - 2026-08-05 8-K Item 2.02, Results of Operations and Financial Condition
On August 5, 2026, Tenaya Therapeutics, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2026 (“Earnings Press Release”). The full text of the Earnings Press Release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The information furnished in this Item 2.02 and Item 9.01 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. the 8-K · retrieved 2026-11-20 15:04 UTC
Each excerpt is the first part of the item's own text, copied as filed and cut at a word; the filing has the rest.
POSSIBLE MATCHES · GROUPED BY SOURCE8. Enforcement by agency
EPA ECHO facilities (3)
possible match: matched by name only, not merged (3)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchTENAYA THERAPEUTICS · exact name match to 'Tenaya Therapeutics, Inc.' (no other entity shares the name) · sx:epa:110071261049 Compare
- possible matchTENAYA THERAPEUTICS · exact name match to 'Tenaya Therapeutics, Inc.' (no other entity shares the name) · sx:epa:110071380261 Compare
- possible matchTENAYA THERAPEUTICS INC · exact legal name · sx:epa:110070425784 Compare
Each record's own page holds its date and the agency document. Matched by exact name only; none of these is counted in the headline.
AS FILED · LARGEST HOLDERS10. 13F institutional holders
| Rank | Holder (13F filer) | Value held | As of | Source | Retrieved | Report |
|---|---|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | $5,247,833 | 2026-06-30 | SEC 13F filing | 2026-11-20 15:04 UTC | Report an error |
| 2 | MILLENNIUM MANAGEMENT LLC | $4,752,153 | 2026-06-30 | SEC 13F filing | 2026-11-20 15:04 UTC | Report an error |
| 3 | CITADEL ADVISORS LLC | $3,375,303 | 2026-06-30 | SEC 13F filing | 2026-11-20 15:04 UTC | Report an error |
| 4 | RENAISSANCE TECHNOLOGIES LLC | $3,164,161 | 2026-06-30 | SEC 13F filing | 2026-11-20 15:04 UTC | Report an error |
| 5 | BlackRock, Inc. | $2,962,845 | 2026-06-30 | SEC 13F filing | 2026-11-20 15:04 UTC | Report an error |
| 6 | Empery Asset Management, LP | $2,855,228 | 2026-06-30 | SEC 13F filing | 2026-11-20 15:04 UTC | Report an error |
| 7 | MARSHALL WACE, LLP | $2,592,352 | 2026-06-30 | SEC 13F filing | 2026-11-20 15:04 UTC | Report an error |
| 8 | Burkehill Global Management, LP | $1,478,200 | 2026-06-30 | SEC 13F filing | 2026-11-20 15:04 UTC | Report an error |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | $1,356,805 | 2026-06-30 | SEC 13F filing | 2026-11-20 15:04 UTC | Report an error |
| 10 | ADAR1 Capital Management, LLC | $1,149,670 | 2026-06-30 | SEC 13F filing | 2026-11-20 15:04 UTC | Report an error |
13F as filed: the holder's own report of its position value at the quarter end.
POSSIBLE MATCHES · LICENCES, PERMITS, CITY AND STATE RECORDS13. Permits and local records
5 state and city records carry this company's exact name, from 3 sources. Possible matches only.
California business registrations (3)
possible match: matched by name only, not merged (3)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchTenaya Therapeutics, Inc. · exact legal name · sx:cabiz:sf:1149240-06-171-1061031 Compare
- possible matchTenaya Therapeutics, Inc. · exact legal name · sx:cabiz:sf:1127115-11-161-1061031 Compare
- possible matchTenaya Therapeutics, Inc. · exact legal name · sx:cabiz:sf:1127116-11-161-1061031 Compare
ClinicalTrials.gov (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchTenaya Therapeutics · exact name match to 'Tenaya Therapeutics, Inc.' (no other entity shares the name) · sx:ctgov:h48db78ecef1105b8 Compare
State licences (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchTENAYA THERAPEUTICS, INC. · exact legal name · sx:elic:ctcred:1750182 Compare
WHAT THIS PAGE READ
Sources
JSON · MCP · API
API and agents
The same profile as JSON: GET /company/1858848.json. The MCP server and the records API return the same data: GET /v1/record/sx:sec:0001858848. Every source URL used is listed in the file.
Get the evidence file, alerts and the API with a free key. Everything on this page stays free to read.